Items where Division is "Current Faculties > Faculty of Medicine > School of Healthcare, Enterprise and Innovation > SHTAC
School of Healthcare, Enterprise and Innovation > SHTAC" and Year is 2017
 | Up a level |
Number of items: 7.
Risk of ophthalmic adverse effects in patients treated with MEK Inhibitors: A systematic review and meta-analysis - Carlos Alves, Inês Ribeiro, Ana Penedones, Diogo Mendes and Francisco Batel Marques
Type: Review
| 2017
| Item not available on this server.
The Promote Study: Patient reported outcome measures online to enhance communication and quality of life after childhood brain tumour - systematic review - Kim Bull, Colin Kennedy, Samantha Hornsey, Jonathan Shepherd, Karen L. Welch and Christopher Morris
Type: Meeting abstract
| 2017
| Item not available on this server.
Evidence for the hERG Liability of antihistamines, antipsychotics, and anti-infective agents: A systematic literature review from the ARITMO project - Lorna Hazell, Emanuel Raschi, Fabrizio De Ponti, Simon H.L. Thomas, Francesco Salvo, Ernst Ahlberg Helgee, Scott Boyer, Miriam Sturkenboom and Saad Shakir
Type: Review
| 2017
| Item not available on this server.
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation - Nicola Huxley, Louise Crathorne, Jo Varley-Campbell, Irina Tikhonova, Tristan Snowsill, Simon Briscoe, Jaime Peters, Mary Bond, Mark Napier and Martin Hoyle
Type: Review
| 2017
| Item not available on this server.
Preferences of parents to avoid oral health outcomes in children: Results of a discrete choice experiment - L. Longworth, J. Singh, O. Onyimadu and J. Lord
Type: Meeting abstract
| 2017
| Item not available on this server.
Preferences of the general population to avoid oral health outcomes: results of A Bayesian discrete choice experiment - L. Longworth, J. Singh, O. Onyimadu and J. Lord
Type: Meeting abstract
| 2017
Azacitidine for treating acute myeloid leukaemia with more than 30 % bone marrow blasts: an Evidence Review Group perspective of a National Institute for Health and Care Excellence single technology appraisal - Irina A. Tikhonova, Martin W. Hoyle, Tristan M. Snowsill, Chris Cooper, Joanna L. Varley-Campbell, Claudius E. Rudin and Ruben E. Mujica Mota
Type: Review
| 2017
| Item not available on this server.